Mitochondrial abnormalities in inclusion-body myositis

Neurology

Volumn 66, Issue 2 SUPPL. 1, 2006, Pages

  Oldfors, A ^a   Moslemi, A R ^a   Jonasson, Lars S ^a   Ohlsson, M ^a   Kollberg, G ^a   Lindberg, C ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CARNITINE; CREATINE; DNA DIRECTED DNA POLYMERASE GAMMA; FOLIC ACID; MITOCHONDRIAL DNA; PROSTAGLANDIN SYNTHASE; RIBOFLAVIN; RIBOSOME RNA; THIAMINE; UBIDECARENONE; CYTOCHROME C OXIDASE; TRANSFER RNA;

ANT1 GENE; C10ORF2 GENE; CELL FUNCTION; CONFERENCE PAPER; DNA SEQUENCE; ENZYME DEFICIENCY; GENE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL GENETICS; MUSCLE CELL; MUSCLE WEAKNESS; OXIDATIVE PHOSPHORYLATION; POINT MUTATION; POLG1 GENE; PRIORITY JOURNAL; RESPIRATORY CHAIN; RNA GENE; SEQUENCE ANALYSIS; AGING; ENZYMOLOGY; GENETICS; METABOLISM; MITOCHONDRIAL MYOPATHY; MOLECULAR GENETICS; MUSCLE MITOCHONDRION; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REVIEW;

AGING; BASE SEQUENCE; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX IV; HUMANS; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL MYOPATHIES; MOLECULAR SEQUENCE DATA; MUSCLE FIBERS; MUTATION; MYOSITIS, INCLUSION BODY; OXIDATIVE PHOSPHORYLATION; RNA, TRANSFER; SEQUENCE DELETION;

EID: 33644860811     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000192127.63013.8d     Document Type: Conference Paper

References (63)

1. Carpenter S, Karpati G, Eisen A. A morphologic study in polymyositis: clues to pathogenesis of different types. In: Bradley W, ed. Recent Advances in Myology. Amsterdam: Excerpta Medica, 1975:374-379.
2. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971;25:240-248.
3. DiMauro S. Mitochondrial diseases. Biochim Biophys Acta 2004;1658:80-88.
4. Oldfors A, Tulinius M. Mitochondrial encephalomyopathies. J Neuropathol Exp Neurol 2003;62:217-227.
5. Smeitink J, vandenHeuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2001;2:342-352.
6. Larsson NG, Oldfors A. Mitochondrial myopathies. Acta Physiol Scand 2001;171:385-393.
7. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689-692.
8. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000;289:782-785.
9. Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001;28:223-231.
10. VanGoethem G, Dermaut B, Lofgren A, Martin JJ, VanBroeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001;28:211-212.
11. Elpeleg O, Mandel H, Saada A. Depletion of the other genomemitochondrial DNA depletion syndromes in humans. J Mol Med 2002;80:389-396.
12. Liu VW, Zhang C, Nagley P. Mutations in mitochondrial DNA accumulate differentially in three different human tissues during ageing. Nucleic Acids Res 1998;26:1268-1275.
13. Münscher C, Rieger T, Müller-Höcker J, Kadenbach B. The point mutation of mitochondrial DNA characteristic for MERRF disease is found also in healthy people of different ages. FEBS Lett 1993;317:27-30.
14. Baumer A, Zhang CF, Linnane AW, Nagley P. Age-related human mtDNA deletions: a heterogeneous set of deletions arising at a single pair of directly repeated sequences. Am J Hum Genet 1994;54:618-630.
15. Zhang C, Baumer A, Maxwell RJ, Linnane AW, Nagley P. Multiple mitochondrial DNA deletions in an elderly human individual. FEBS Lett 1992;297:34-38.
16. Wallace DC. Mitochondrial genetics - a paradigm for aging and degenerative diseases. Science 1992;256:628-632.
17. Müller-Höcker J. Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. J Neurol Sci 1990;100:14-21.
18. Fayet G, Jansson M, Sternberg D, et al. Ageing muscle: clonal expansions of mitochondrial DNA point mutations and deletions cause focal impairment of mitochondrial function. Neuromuscul Disord 2002;12:484-493.
19. Trifunovic A, Wredenberg A, Falkenberg M, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004;429:417-423.
20. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978;28:8-17.
21. Rifai Z, Welle S, Kamp C, Thornton CA. Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995;37:24-29.
22. Oldfors A, Moslemi AR, Fyhr IM, Holme E, Larsson NG, Lindberg C. Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995;54:581-587.
23. Horvath R, Fu K, Johns T, Genge A, Karpati G, Shoubridge EA. Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis. J Neuropathol Exp Neurol 1998;57:396-403.
24. Molnar M, Schröder JM. Pleomorphic mitochondrial and different filamentous inclusions in inflammatory myopathies associated with mtDNA deletions. Acta Neuropathol (Berl) 1998;96:41-51.
25. Dahlbom K, Lindberg C, Oldfors A. Inclusion body myositis: morphological clues to correct diagnosis. Neuromuscul Disord 2002;12:853-857.
26. Oldfors A, Larsson NG, Lindberg C, Holme E. Mitochondrial DNA deletions in inclusion body myositis. Brain 1993;116:325-336.
27. Oldfors A, Moslemi AR, Holme E, Lindberg C. Mitochondrial alterations in sporadic inclusion-body myositis. In: Askanas V, Serratrice G, Engel WK, eds. Inclusion body myositis and myopathies. Cambridge: Cambridge University Press, 1998:306-317.
28. Santorelli FM, Sciacco M, Tanji K, et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 1996;39:789-795.
29. Desnuelle C, Paquis V, Paul R, et al. Mitochondrial DNA analysis in muscle of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. In: Askanas V, Serratrice G, Engel WK, eds. Inclusion body myositis and myopathies. Cambridge: Cambridge University Press, 1998:318-328.
30. Moslemi AR, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat 1997;10:381-386.
31. Samuels DC, Schon EA, Chinnery PF. Two direct repeats cause most human mtDNA deletions. Trends Genet 2004;20:393-398.
32. Johnston W, Karpati G, Carpenter S, Arnold D, Shoubridge EA. Late-onset mitochondrial myopathy. Ann Neurol 1995;37:16-23.
33. Moslemi AR, Melberg A, Holme E, Oldfors A. Clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia. Ann Neurol 1996;40:707-713.
34. Brierley EJ, Johnson MA, Lightowlers RN, James OFW, Turnbull DM. Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol 1998;43:217-223.
35. Korhonen JA, Pham XH, Pellegrini M, Falkenberg M. Reconstitution of a minimal mtDNA replisome in vitro. Embo J 2004;23:2423-2429.
36. Wanrooij S, Luoma P, vanGoethem G, vanBroeckhoven C, Suomalainen A, Spelbrink JN. Twinkle and POLG defects enhance age-dependent accumulation of mutations in the control region of mtDNA. Nucleic Acids Res 2004;32:3053-3064.
37. Tyynismaa H, Sembongi H, Bokori-Brown M, et al. Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number. Hum Mol Genet 2004;13:3219-3227.
38. Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain 1997;120:39-45.
39. Levine TD, Pestronk A. Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment. Muscle Nerve 1998;21:1724-1728.
40. Lodi R, Taylor DJ, Tabrizi SJ, et al. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain 1998;121:2119-2126.
41. Argov Z, Taivassalo T, DeStefano N, Genge A, Karpati G, Arnold DL. Intracellular phosphates in inclusion body myositis - a 31P magnetic resonance spectroscopy study. Muscle Nerve 1998;21:1523-1525.
42. Pak JW, Herbst A, Bua E, Gokey N, McKenzie D, Aiken JM. Mitochondrial DNA mutations as a fundamental mechanism in physiological declines associated with aging. Aging Cell 2003;2:1-7.
43. Aiken J, Bua E, Cao Z, et al. Mitochondrial DNA deletion mutations and sarcopenia. Ann NY Acad Sci 2002;959:412-423.
44. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996;93:1314-1319.
45. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. beta-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993;4:815-818.
46. Askanas V, Alvarez RB, Engel WK. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993;34:551-560.
47. Carrozzo R, Rizza T, Stringaro A, et al. Maternally-inherited Leigh syndrome-related mutations bolster mitochondrial-mediated apoptosis. J Neurochem 2004;90:490-501.
48. Ikezoe K, Nakagawa M, Yan C, Kira J, Goto Y, Nonaka I. Apoptosis is suspended in muscle of mitochondrial encephalomyopathies. Acta Neuropathol (Berl) 2002;103:531-540.
49. Vattemi G, Tonin P, Filosto M, Spagnolo M, Rizzuto N, Tomelleri G. T-cell anti-apoptotic mechanisms in inflammatory myopathies. J Neuroimmunol 2000;111:146-151.
50. Nagaraju K, Casciola-Rosen L, Rosen A, et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 2000;164:5459-5465.
51. Fyhr IM, Lindberg C, Oldfors A. Expression of Bcl-2 in inclusion body myositis. Acta Neurol Scand 2002;105:403-407.
52. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997;120:929-938.
53. DiMauro S, Mancuso M, Naini A. Mitochondrial encephalomyopathies: therapeutic approach. Ann NY Acad Sci 2004;1011:232-245.
54. Bendahan D, Desnuelle C, Vanuxem D, et al. P-31 NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme-Q in mitochondrial myopathies. Neurology 1992;42:1203-1208.
55. Chen RS, Huang CC, Chu NS. Coenzyme Q(10) treatment in mitochondrial encephalomyopathies - Short-term double-blind, crossover study. Eur Neurol 1997;37:212-218.
56. Yamada T, Minohara M, Imaiso Y, et al. High-dose vitamin C therapy for inclusion body myositis. Fukuoka Igaku Zasshi 2001;92:99-104.
57. Schon EA, DiMauro S. Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem 2003;10:2523-2533.
58. Clark KM, Bindoff LA, Lightowlers RN, et al. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet 1997;16:222-224.
59. Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, Shoubridge EA. Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 1999;8:1047-1052.
60. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003;35:31-35.
61. Taivassalo T, Shoubridge EA, Chen J, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001;50:133-141.
62. Sciacco M, Bonilla E, Schon EA, DiMauro S, Moraes CT. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 1994;3:13-19.
63. Moslemi AR, Melberg A, Holme E, Oldfors A. Autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions. Neurology 1999;53:79-84.